Your browser doesn't support javascript.
loading
SLC1A5 is a novel biomarker associated with ferroptosis and the tumor microenvironment: a pancancer analysis.
Chen, Peng; Jiang, YongAn; Liang, JiaWei; Cai, JiaHong; Zhuo, Yi; Fan, HengYi; Yuan, RaoRao; Cheng, ShiQi; Zhang, Yan.
Afiliación
  • Chen P; Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, P.R. China.
  • Jiang Y; Department of Medical, Nanchang University, Nanchang 330006, Jiangxi, P.R. China.
  • Liang J; Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, P.R. China.
  • Cai J; Department of Medical, Nanchang University, Nanchang 330006, Jiangxi, P.R. China.
  • Zhuo Y; Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, P.R. China.
  • Fan H; Department of Medical, Nanchang University, Nanchang 330006, Jiangxi, P.R. China.
  • Yuan R; Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, P.R. China.
  • Cheng S; Department of Medical, Nanchang University, Nanchang 330006, Jiangxi, P.R. China.
  • Zhang Y; Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, P.R. China.
Aging (Albany NY) ; 15(15): 7451-7475, 2023 08 10.
Article en En | MEDLINE | ID: mdl-37566748
Solute carrier family 1 member 5 (SLC1A5) is a member of the solute carrier (SLC) superfamily of transporters and plays an important role in tumors as a key transporter of glutamine into cells. However, the relationship between SLC1A5, which is involved in immune regulation, and immune cell infiltration in the tumor microenvironment has not been elucidated, and the relationship between SLC1A5 and ferroptosis is rarely reported. Therefore, we comprehensively analyzed the expression level of SLC1A5 across cancers and compared it with that in normal tissues. Then, the relationship between SLC1A5 expression and the tumor immune microenvironment was analyzed by single-cell analysis, gene set enrichment analysis (GSEA), and Tumor Immune Estimation Resource (TIMER). Next, the correlations of the SLC1A5 expression level with immunotherapy response, immunomodulator expression, tumor mutation burden (TMB) and microsatellite instability (MSI) were evaluated. Finally, in vitro experiments verified that SLC1A5 participates in ferroptosis of glioma cells to regulate tumor progression. Our results indicated that SLC1A5 is aberrantly expressed in most cancer types and closely associated with prognosis. The GSEA results showed that SLC1A5 is involved in immune activation processes and closely related to the infiltration levels of different immune cells in different cancer types. Upon further investigation, we found that SLC1A5 is a suppressor of ferroptosis in glioma, and SLC1A5 knockdown inhibited the proliferation and migration of glioma cells in vitro. In conclusion, we conducted a pancancer analysis of SLC1A5, demonstrated its role as a prognostic biomarker in cancer patients and explored its potential biological functions.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ferroptosis / Glioma Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Aging (Albany NY) Asunto de la revista: GERIATRIA Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ferroptosis / Glioma Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Aging (Albany NY) Asunto de la revista: GERIATRIA Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos